Table 4.

Measurement properties of SF-6D in different countries/districts and different disease groups

	Quality of PBM and evidence
	Construct validity			Test-retest reliability			Responsiveness
China	±	H	[28, 42, 82, 87, 89, 90]
Hong Kong	+	H	[17, 18, 78, 80]	+	La	[79]	±	La	[81]
Japan	–	H	[66]
Singapore	+	H	[12, 40, 84, 86]	±	Va.b	[12]	±	La	[12, 24]
South Korea							+	H	[33]
Thailand	±	H	[61]
Cancer	+	H	[73]				±	La	[81]
Eye disease							+	La	[24]
General population	±	H	[28, 66, 80, 89]
Genitourinary disease	±	H	[90]
Heart disease	±	H	[82]
Hepatitis	±	H	[78]
Kidney disease	+	H	[86]
Mental disorders	+	H	[12]	±	Va,b	[12]	±	La	[12]
Multiple conditions	±	H	[61]
Musculoskeletal disease	+	H	[18, 87]
Respiratory disease	+	H	[17]
Rheumatic disease	+	H	[40, 84]
Stroke							+	H	[33]
Thyroid disease				+	La	[79]

Quality of PBM: + indicates sufficient results; ± indicates inconsistent results; – indicates insufficient results

Italicised font indicates that grading is based on no more than three studies

SF-6D Short Form-6 Dimensions, PBM preference-based measure, ROB risk of bias

Quality of evidence: H indicates high; L indicates low; V indicates very low

^aQuality downgraded by 2 levels due to ROB

^bQuality downgraded by 1 level due to imprecision